Metabolic Dysfunction and Hepatic Steatosis in Chronic Hepatitis B

Key Takeaways

• Hepatic steatosis was observationally associated with lower HBV activity and a higher likelihood of HBsAg loss over time.
• This association appeared stronger when steatosis was moderate to severe, consistent with patterns reported across longitudinal studies.
• Diabetes, obesity or central obesity, and hypertension were linked to cirrhosis, hepatocellular carcinoma, and mortality, while management discussion emphasized integrated viral and metabolic risk assessment rather than formal changes to care standards.

In a Gut and Liver review, observational evidence suggested that hepatic steatosis tracked with lower HBV activity and a greater likelihood of HBsAg seroclearance or seroconversion. At the same time, broader metabolic dysfunction tracked with poorer liver-related outcomes, separating the effects of liver fat from systemic metabolic burden. Together, the overlap was framed as a dual-burden condition with opposing signals from steatosis and metabolic risk.

Published online in Gut and Liver on April 23, 2026, the paper synthesized mechanistic, clinical, and population-based evidence on this overlap. It examined the coexistence of chronic hepatitis B and metabolic dysfunction-associated steatotic liver disease across epidemiology, natural history, treatment response, and prognosis. The authors noted that chronic hepatitis B affects 316 million people worldwide, while MASLD affects about 38% of the general adult population. This framing separated hepatic steatosis from systemic metabolic dysfunction as related but not interchangeable contributors to prognosis.

Across studies of chronic hepatitis B and MASLD, hepatic steatosis was associated with lower HBV DNA, lower HBsAg titers, and higher rates of HBsAg seroclearance and seroconversion. That pattern appeared stronger in patients with moderate to severe steatosis and aligned with the review’s functional cure framing. As one cited example, a cohort of 4,707 CHB-SLD patients showed a 38% lower mortality risk than matched non-SLD chronic hepatitis B patients, although the authors emphasized that causality remains uncertain. Overall, the steatosis signal in the synthesized evidence pointed to lower virologic activity during longitudinal follow-up, but may reflect confounding factors such as preserved liver function or nutritional status.

By contrast, metabolic dysfunction was consistently associated with cirrhosis, hepatocellular carcinoma, and mortality in chronic hepatitis B. Risk increased with the number and severity of metabolic abnormalities, underscoring a dose-related burden across cohorts. Diabetes mellitus, central obesity, and hypertension were the main comorbidities named, and diabetes was presented as the strongest predictor of poor outcomes. The adverse prognostic signal therefore reflected broader metabolic burden rather than hepatic steatosis alone.

Management discussion centered on viral suppression alongside baseline and periodic reassessment of cardiometabolic risk, particularly in patients with higher metabolic burden. The authors highlighted the need for integrated and personalized risk stratification rather than formal changes to existing treatment guidelines. They also noted that no approved therapy specifically targets this overlap, and current treatment algorithms do not incorporate metabolic risk stratification. Earlier nucleos(t)ide analogue therapy may be considered in selected patients with high metabolic burden, although that timing question remains unresolved. Data on antiviral response were mixed, with some studies reporting slower HBV DNA suppression or lower ALT normalization in MASLD. Causality remained uncertain because reverse causality, survival bias, ultrasonography-based misclassification, and better nutritional status could explain the steatosis association, leaving prospective mechanistic studies still needed.